Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Nur Aininie Yusoh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, West China Hospital of Sichuan University, S…. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Triple Negative Breast Neoplasms, Androstadienes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Llywodraeth Cymru, National Natural Science Foundation of China, Geran Putra Inisiatif Siswazah.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) remains the breast cancer subtype with the poorest prognosis. While PARP inhibitors (PARPi) effectively target BRCA1/2‐mutant TNBCs via synthetic lethality, most TNBCs are BRCA1/2 wild‐type. Synergistic drug combinations may expand PARPi efficacy to BRCA‐proficient TNBC. To identify new PARPi combinations, we screened a library of 166 FDA‐approved oncology drugs for synergy with Olaparib in TNBC cells. We found that Exemestane, an aromatase inhibitor, synergized with Olaparib, significantly decreasing IC 50 values and clonogenicity while increasing DNA damage and apoptosis. The mechanistic basis for this synergy was rationalized by the previously unreported ability of Exemestane to induce replication stress via reactive oxygen species (ROS) generation and oxidative stress. This combination had low cytotoxicity toward normal breast epithelial cells, and Exemestane has no reported severe toxicity as a monotherapy. The combination of Olaparib and Exemestane was able to achieve enhanced tumor growth inhibition in a murine xenograft model, greater than either drug employed as a single agent, and GO and KEGG enrichment analysis indicated alterations in pathways associated with cell death in response to Exemestane and Olaparib treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, West China Hospital of Sichuan University, Sichuan University, Chengdu, China.
- UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Malaysia.
- Department of Microbiology, Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia, Serdang, Malaysia.
- Malaysia Genome and Vaccine Institute, National Institutes of Biotechnology Malaysia, Kajang, Malaysia.
- Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Malaysia.
- Department of Chemistry, Faculty of Science and Engineering, Swansea University, UK.
ORCID-Profile: Martin R Gill
Förderung
- Llywodraeth Cymru
- National Natural Science Foundation of China
- Geran Putra Inisiatif Siswazah
Zitieren
APA
Yusoh, N. A., Su, L., Chia, S. L., Tian, X., Ahmad, H., & Gill, M. R. (2025). Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.70093
Vancouver
Yusoh NA, Su L, Chia SL, Tian X, Ahmad H, Gill MR. Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer. Molecular Oncology. 2025. doi:10.1002/1878-0261.70093
BibTeX
@article{Yusoh2025,
author = {Yusoh, Nur Aininie and Su, Liping and Chia, Suet Lin and Tian, Xiaohe and Ahmad, Haslina and Gill, Martin R},
title = {Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70093}
}
EUVIMED